![Joan Manthis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joan Manthis
Corporate Officer/Principal bij Bausch & Lomb (Australia) Pty Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Norbert Walther | M | - |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 15 jaar |
Chris van Niekerk | M | - |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 17 jaar |
Robert Rosewell Chai-Onn | M | 52 |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | - |
Howard Schiller | M | 61 |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | - |
Greg J. Minton | M | 61 |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 18 jaar |
Ben Frewin | M | - |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 18 jaar |
Jamshed Ahmed | M | - |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Thomas A. Shea | M | 64 |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
William T. Pappafotopoulos | M | - |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Thomas J. Wilson | M | - |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | 1 jaar |
Pierre V. Trân | M | 64 |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Timothy Barberich | M | 76 |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Walter Piskorski | M | 75 |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Randall D. Marshall | M | - |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 7 | 50.00% |
Australië | 7 | 50.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Joan Manthis
- Persoonlijk netwerk